148 related articles for article (PubMed ID: 15621733)
1. Homoharringtonine: a new treatment option for myeloid leukemia.
Luo CY; Tang JY; Wang YP
Hematology; 2004 Aug; 9(4):259-70. PubMed ID: 15621733
[TBL] [Abstract][Full Text] [Related]
2. Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.
Quintás-Cardama A; Cortes J
IDrugs; 2008 May; 11(5):356-72. PubMed ID: 18465678
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
Quintás-Cardama A; Kantarjian H; Garcia-Manero G; O'Brien S; Faderl S; Estrov Z; Giles F; Murgo A; Ladie N; Verstovsek S; Cortes J
Cancer; 2007 Jan; 109(2):248-55. PubMed ID: 17154172
[TBL] [Abstract][Full Text] [Related]
4. Homoharringtonine for the treatment of chronic myelogenous leukemia.
Quintás-Cardama A; Cortes J
Expert Opin Pharmacother; 2008 Apr; 9(6):1029-37. PubMed ID: 18377344
[TBL] [Abstract][Full Text] [Related]
5. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia.
Feldman EJ; Seiter KP; Ahmed T; Baskind P; Arlin ZA
Leukemia; 1996 Jan; 10(1):40-2. PubMed ID: 8558935
[TBL] [Abstract][Full Text] [Related]
6. Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors.
Visani G; Russo D; Ottaviani E; Tosi P; Damiani D; Michelutti A; Manfroi S; Baccarani M; Tura S
Leukemia; 1997 May; 11(5):624-8. PubMed ID: 9180282
[TBL] [Abstract][Full Text] [Related]
7. Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia.
Chung C
Am J Health Syst Pharm; 2014 Feb; 71(4):279-88. PubMed ID: 24481153
[TBL] [Abstract][Full Text] [Related]
8. HPLC analysis of harringtonine and homoharringtonine in the needles of Cephalotaxus griffithii alkaloid fraction and cytotoxic activity on chronic myelogenous leukaemia K562 cell.
Moirangthem DS; Borah JC; Laishram S; Kalita MC; Talukdar NC
Nat Prod Res; 2014; 28(18):1503-6. PubMed ID: 24787645
[TBL] [Abstract][Full Text] [Related]
9. Omacetaxine mepesuccinate in chronic myeloid leukemia.
Al Ustwani O; Griffiths EA; Wang ES; Wetzler M
Expert Opin Pharmacother; 2014 Nov; 15(16):2397-405. PubMed ID: 25301179
[TBL] [Abstract][Full Text] [Related]
10. Homoharringtonine and omacetaxine for myeloid hematological malignancies.
Lü S; Wang J
J Hematol Oncol; 2014 Jan; 7():2. PubMed ID: 24387717
[TBL] [Abstract][Full Text] [Related]
11. MiR-370 sensitizes chronic myeloid leukemia K562 cells to homoharringtonine by targeting Forkhead box M1.
Zhou M; Zeng J; Wang X; Guo Q; Huang T; Shen H; Fu Y; Wang L; Jia J; Chen C
J Transl Med; 2013 Oct; 11():265. PubMed ID: 24148180
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies.
Kantarjian H; O'Brien S; Jabbour E; Barnes G; Pathak A; Cortes J
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):13-21. PubMed ID: 25458084
[TBL] [Abstract][Full Text] [Related]
13. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia.
Feldman E; Arlin Z; Ahmed T; Mittelman A; Puccio C; Chun H; Cook P; Baskind P
Leukemia; 1992 Nov; 6(11):1185-8. PubMed ID: 1434802
[TBL] [Abstract][Full Text] [Related]
14. [Research Progress of Homoharringtonine Effect on IM-resistant Chronic Myelogenous Leukemia -Review].
Wang Q; Li YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):596-599. PubMed ID: 28446318
[TBL] [Abstract][Full Text] [Related]
15. Effects of the combination of decitabine and homoharringtonine in SKM-1 and Kg-1a cells.
Geng S; Yao H; Weng J; Tong J; Huang X; Wu P; Deng C; Li M; Lu Z; Du X
Leuk Res; 2016 May; 44():17-24. PubMed ID: 26991610
[TBL] [Abstract][Full Text] [Related]
16. Induction of apoptosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells.
Mai WY; Lin MF
Chin Med J (Engl); 2005 Mar; 118(6):487-92. PubMed ID: 15788130
[TBL] [Abstract][Full Text] [Related]
17. Homoharringtonine: history, current research, and future direction.
Kantarjian HM; Talpaz M; Santini V; Murgo A; Cheson B; O'Brien SM
Cancer; 2001 Sep; 92(6):1591-605. PubMed ID: 11745238
[TBL] [Abstract][Full Text] [Related]
18. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.
O'Brien S; Kantarjian H; Koller C; Feldman E; Beran M; Andreeff M; Giralt S; Cheson B; Keating M; Freireich E; Rios MB; Talpaz M
Blood; 1999 Jun; 93(12):4149-53. PubMed ID: 10361112
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of Homoharringtonine for the treatment of children with refractory or recurrent acute myelogenous leukemia: a pediatric oncology group study.
Bell BA; Chang MN; Weinstein HJ
Med Pediatr Oncol; 2001 Aug; 37(2):103-7. PubMed ID: 11496347
[TBL] [Abstract][Full Text] [Related]
20. Homoharringtonine targets Smad3 and TGF-β pathway to inhibit the proliferation of acute myeloid leukemia cells.
Chen J; Mu Q; Li X; Yin X; Yu M; Jin J; Li C; Zhou Y; Zhou J; Suo S; Lu D; Jin J
Oncotarget; 2017 Jun; 8(25):40318-40326. PubMed ID: 28454099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
